Novo Nordisk A/S (NYSE:NVO) & Pasithea Therapeutics (NASDAQ:KTTA) Head-To-Head Analysis

Novo Nordisk A/S (NYSE:NVO – Get Free Report) and Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Institutional and Insider Ownership 11.5% of Novo […]

Leave a Reply

Your email address will not be published.

Previous post Halozyme Therapeutics (NASDAQ:HALO) Receives Buy Rating from HC Wainwright
Next post Intercontinental Exchange (NYSE:ICE) Receives Outperform Rating from Royal Bank of Canada